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Abstract: Knowledge on lymph node metastases is crucial for the prognosis and treatment 
of prostate cancer patients. Conventional anatomic imaging often fails to differentiate 
benign from metastatic lymph nodes. Pelvic lymph node dissection is an invasive 
technique and underestimates the extent of lymph node metastases. Therefore, there is a 
need for more accurate non-invasive diagnostic techniques. Molecular and functional 
imaging has been subject of research for the last decades, in this respect. Therefore, in this 
article the value of imaging techniques to detect lymph node metastases is reviewed.  
These techniques include scintigraphy, sentinel node imaging, positron emission 
tomography/computed tomography (PET/CT), diffusion weighted magnetic resonance 
imaging (DWI MRI) and magnetic resonance lymphography (MRL). Knowledge on 
pathway and size of lymph node metastases has increased with molecular and functional 
imaging. Furthermore, improved detection and localization of lymph node metastases will 
enable (focal) treatment of the positive nodes only.  
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1. Introduction 
There is increasing knowledge of lymph node metastases in patients with prostate cancer. This 
knowledge helps to predict prognosis [1,2] and is important to optimize treatment planning [3].  
1.1. Conventional Anatomic Imaging 
The normal upper limit of the short-axis diameter of pelvic lymph nodes is 7–10 mm depending on 
the location. However, up to 80% of metastatic lymph nodes in prostate cancer have a short axis 
diameter smaller than 7 mm [3,4]. Therefore, it is not surprising that a limited sensitivity is reported 
for conventional computed tomography (CT) and magnetic resonance imaging (MRI), as they rely on 
the size criteria to differentiate between benign and malignant lymph nodes. A pooled sensitivity of 
42% and 39% and pooled specificity of 82% and 82% for CT and MRI have been reported in a  
meta-analysis of Hovels et al. [5]. The used cutoff value varied between 5 and 15 mm. Hilton et al. 
showed that the sensitivity improved from 37% to 93% when lowering the threshold diameter  
from ≥10 mm to ≥4 mm, but this is at the cost of specificity which drops from 100% to 58% [4]. 
1.2. Pelvic Lymph Node Dissection (PLND) 
PLND is widely used to access lymph node metastasis in prostate cancer. It can be omitted in 
patients with less than 5% risk of lymph node involvement, but is otherwise advised [5]. This 
technique is invasive and underestimates lymph node involvement, as in approximately 40%–50% of 
patients metastatic lymph nodes are found outside the standard resection area [6,7]. At the cost of 
higher complication rates, extended PLND shows better results. However, recently Joniau et al. have 
shown that a rather high number (13%) of metastatic lymph nodes are missed with extended PLND  
as well [8].  
1.3. Rationale for Molecular and Functional Imaging 
Because of the limitations of conventional anatomic imaging and PLND to assess lymph node 
metastases accurately, alternative strategies are needed. Research focuses on the ability of molecular 
and functional imaging to differentiate metastatic from benign lymph nodes in vivo, using direct or 
indirect methods. Direct methods assess metabolic behavior, expression of structures located at the cell 
membrane such as antibodies and receptors and molecular diffusion of metastases. Indirect methods 
trace the lymphatic route from the primary tumor or determine nano-particle incorporation in 
macrophages in non-metastatic lymph nodes.  
In this article, we present a literature overview of the molecular and functional imaging techniques. 
See Table S1 for an overview of the imaging modalities and in short their pro’s and con’s. 
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2. Molecular and Functional Imaging  
2.1. Planar Scintigraphy, Single-Photon Emission Computed Tomography (SPECT) and  
Gamma Probe 
In scintigraphy and SPECT, a gamma ray emitting radionuclide coupled to a molecule that ensures 
specific accumulation to a tissue of interest (tracer) is admitted to the patient. These gamma rays are 
detected by an external gamma camera. With scintigraphy, two-dimensional images (2D) are 
reconstructed. With SPECT, the location of the tracer is calculated and a three-dimensional image (3D) 
is reconstructed. SPECT can be combined with conventional CT or MRI to add anatomical to 
functional information (SPECT/CT or SPECT/MRI). 
A gamma probe is the simplest gamma ray detector. It is a device with a Geiger-Müller tube or 
scintillation counter. After injection of a radionuclide, in or near the tumor in the case of sentinel node 
imaging, the radioactivity can be located during surgery.  
2.1.1. Sentinel Lymph Node Imaging 
With sentinel lymph node imaging a radiotracer is injected into the prostate under trans rectal 
ultrasound guidance (TRUS). Subsequently, the radiotracer enters the lymphatics. The first lymph 
node stations that are reached are called sentinel lymph nodes. These nodes can be detected prior 
surgery on planar scintigraphy or SPECT. During surgery the lymph nodes with radiotracer uptake can 
be detected with a gamma detecting probe [9]. 
The most commonly used radiotracer is 99mTC-nanocolloid. Nanocolloid accumulates in the sentinel 
lymph node [10], which can then be removed and analyzed by immunohistochemistry in more detail as 
compared to the standard pathological procedure. The rationale behind this procedure is that 
metastases reach these sentinel nodes first, before spreading further through the body, either lymphatic 
or hematogeneous. If the sentinel lymph node is free of tumor cells a further PLND can be avoided.  
This technique has changed our knowledge on lymph node drainage of prostate cancer. New maps 
of lymph node drainage were conducted [11,12]. This showed 66% of patients had sentinel lymph 
nodes outside the used standard target volume for whole pelvic radiotherapy [12]. This may explain 
the variable and somewhat disappointing radiation results with radiation therapy [13]. 
In 2011, Sadeghi et al. performed a meta-analysis on sentinel node mapping in prostate cancer. The 
pooled detection rate was 94% [14]. The Augsberg group published the results of until now the largest 
study on sentinel node mapping [15]. Their reported detection rate was 98%. However, this reflects 
only the intraoperative detection of at least one sentinel node. In 24% of the patients not all the 
preoperatively visible sentinel nodes could be harvested during surgery. Also, in 40% of patients 
additional sentinel nodes were found intra operatively. Furthermore, when lymph nodes are fully 
replaced by metastasis, the afferent lymph will be directed to other nodes [16]. These nodes will not be 
positive on sentinel node imaging resulting in false-negative findings. A sub analysis of the Augsberg 
group showed a mean false-negative rate of 6%. The false negative rate was shown to correlate with 
the Gleason Score: In patients with a Gleason Score of 4 + 3 the false negative rate was 4%, whereas 
the false negative rate in patients with a Gleason Score of >8 was 14% [15]. Therefore, sentinel lymph 
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node imaging seems to be of value mainly in primary prostate cancer patients with a Gleason Score of 
8 or lower.  
2.1.2. Radiolabeled Monoclonal Antibodies and Small Molecules 
Many different antibodies have been under research for therapy and imaging of prostate cancer and 
its metastases [17]. The best-known target is a cell surface protein named prostate specific membrane 
antigen (PSMA). PSMA is extremely over expressed in prostate cancer and its metastases compared to 
other tissues [18]. Only one radiolabeled monoclonal antibody is FDA approved, 111-indium 
capromab pendetide (Prostascint), imaged on planar scintigraphy or SPECT/CT. Although  
initial results showed improvement over conventional imaging, sensitivity and specificity are  
limited [17,19–21]. Recently, Hardie et al. combined SPECT/CT with diffusion weighted MRI and 
found an increased sensitivity and specificity by the addition of MRI [22]. Nevertheless, the main 
disadvantage of Prostascint is the fact that this agent targets PSMAs intracellular domain. Therefore, 
imaging becomes only accessible upon apoptosis or necrosis and not in viable tissue [17,23]. PSMA 
presents also a large extracellular target and therefore, main research is now focused on the 
extracellular domain [24]. Recently, a new antibody J591 directed against the extracellular domain of 
PSMA and labelled with 89Zr showed promising results in tumor bearing animals [25]. In general, 
antibodies have a low plasma clearance associated with a long circulation time and therefore, a high 
background activity leads to useful contrast only in late images. Furthermore, the relative high 
molecular weight limits tissue penetration, especially in tumors with a high interstitial pressure. 
Therefore, besides antibodies, small molecules have been applied as well. Since PSMA shows enzyme 
activity, many small molecule inhibitors have been developed, which have been used for the 
development of tracers for diagnosis and therapy. A first-in men study with high affinity PSMA-avid 
small molecules, 123I-MIP-1072 and 123I-MIP-1095, was recently published by Barrett et al showing 
promising results for detection of lesions with excellent pharmacokinetic and pharmacodynamics 
profiles [26]. Currently, 99mTc-MIP-1404, another PSMA small molecule ligand, is under evaluation in 
an international Phase 2 study in men scheduled for radical prostatectomy at high risk for lymph node 
involvement. The study will evaluate the ability of MIP-1404 to detect disease, using histopathology as 
the gold standard (ClinicalTrials.gov Identifier: NCT01667536). 
In summary, agents targeting the intracellular domain and which are sufficient for use in clinical 
practice seem limited. However, first studies with labeled small molecules targeting PSMA show 
promising initial results for diagnosis and treatment. 
2.2. Positron Emission Tomography (PET)  
In PET imaging, a positron emitting radionuclide (tracer) is admitted to the patient. Such a tracer 
emits indirectly a pair of gamma rays. In general, the tracer is combined to a compound used in body 
metabolism, such as glucose. The system detects the gamma rays and reconstructs 3D images of the 
radiotracer uptake in the body. Nowadays PET is often combined with CT to combine molecular and 
anatomical information. More recent PET can also be combined with MRI.  
  




Malignant tumors show an increased glycolytic activity, which is associated with changes in the 
expression of glycolysis-associated genes occurring during malignant transformation. The most 
important genes are those for glucose transporter subtype-1 and hexokinase. These changes in 
transport and phosphorylation are exploited for tumor imaging with 18F-fluorodeoxyglucose (FDG) by 
positron emission tomography (PET). FDG for PET studies of glucose metabolism was introduced as a 
consequence of autoradiographic and biochemical studies with glucose analogs in different tissues [27]. 
Therefore, in oncology the most common metabolic radiotracer is 18F-fluoro-2-deoxy-D-glucose 
(FDG), an analog of glucose. Unfortunately, in prostate cancer the results with FDG are  
disappointing [28–30], possibly because prostate carcinoma is a slow-growing tumor where glucose 
metabolism is not at all or only moderately increased, resulting in a low, not differentiating, uptake of 
FDG [28]. A further disadvantage for using FDG in prostate cancer is the renal excretion, which can 
obscure pelvic lymph nodes by accumulation of FDG in the bladder [30]. Therefore, FDG PET plays a 
limited role in the detection of lymph node metastases in prostate cancer. 
2.2.2. Choline 
In prostate cancer most PET investigations are performed with choline derivates. Choline tracers are 
incorporated into tumor cells after transport and phosphorylation by choline kinase [31] that is up 
regulated in prostate cancer and prostate cancer metastases [32]. Choline analogs are transported into 
the cells. Subsequently, they are rapidly metabolized to phosphocholine or oxidized by choline 
dehydrogenase and betaine-aldehyde dehydrogenase to betaine. The latter occurs mainly in the liver 
and the kidneys. The phosphorylation of choline by choline kinase represents the first and obligatory 
step for the incorporation of choline into phosphatidylcholine. The resulting first metabolite, 
phosphocholine, is negatively charged and therefore, trapped within the cell [27]. 
Different tracers have been combined with choline. 11C-choline has the extra advantage that it 
shows only minimal urinary excretion and therefore, minimal activity in the bladder. The reported 
performance of PET/CT for LN metastasis detection varies from 19% to 80% for sensitivity and  
82%–98% for specificity on a patient-by-patient analysis [33]. Results are good in larger nodes but 
sensitivity is limited in lymph nodes smaller than 7 mm [34]. Limited resolution affects the results and 
therefore also the utility. A practical disadvantage is the short half-life of 11C of 20 min and therefore 
requiring an onsite cyclotron.  
18F-choline has a half-life of the isotope of 110 min and is, as a consequence, more easily available. 
On the other hand, 18F-choline has greater urinary excretion than 11C-choline. Nonetheless, as 
pathological uptake begins one-minute post injection (before urinary excretion). This is less a problem 
than in FDG PET/CT. In benign prostate tissues, a decrease of tracer accumulation was observed with 
time, also leading to a higher contrast between tumour and normal tissue. It has been suggested that 
this is due to a dephosphorylation of 18F-phosphorylfluoro-choline by prostatic acid phosphatase, an 
enzyme that is specific for prostate tissues [35,36]. Normal prostate tissue, as well as prostate 
hyperplasia, contains higher levels of prostatic acid phosphatase than prostate carcinoma, which 
accepts phosphocholine and possibly also 18F-phosphorylfluoro-choline as a substrate. Theoretically 
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18F-choline has a somewhat higher resolution because of a shorter positron length path although the 
results are varying. Reported sensitivity and specificity are 10%–100% and 80%–100%, respectively, 
on a patient-by-patient analysis in primary disease [33]. Tilka et al. recently performed a lesion-based 
analysis in 1149 lymph nodes in 56 patients yielding a sensitivity of 40% and a specificity of  
96% [37]. In recurrent disease the detection rate of metastases with choline PET/CT  
shows to be higher when PSA levels increase [37,38]. See Figure 1 for an example of 18F-choline  
PET-CT imaging. 
Figure 1. 18F-choline PET-CT. Patient after radical prostatectomy with slowly increasing 
PSA (current PSA: 1.5 µg/L). The figure shows series of native CT images (A); PET 
images 60 min after the administration of 18F-choline (B) and fused PET-CT images (C) in 
transversal, sagittal and coronal views. The PET images show a small hot spot in the right 
inguinal region with increased isotope uptake. In the PET-CT fused images this spot can be 
identified as a small right inguinal lymph node highly suspect for a metastasis.  
(F: Transverse plane; L: Saggital plane; A: Coronal plane).  
 
In a recent study, simultaneous 18F-choline PET and MRI imaging in the prostate showed to be 
feasible [39] and can potentially improve the current results of choline PET imaging. Further research 
is warranted to see if this combination may also be feasible for lymph node imaging. Choline PET-CT 
is currently mainly helpful in the case of positive lymph nodes. However, a negative result has to be 
handled with care as sensitivity for small lymph node metastases has shown to be limited.  




Acetate has, similar to choline, a role in fatty acid metabolism by participation in cytoplasmic lipid 
synthesis. Fatty acid synthase is an enzymatic protein that catalyses fatty acid biosynthesis and is 
overexpressed in prostate carcinoma compared to normal tissues [40]. The urinary excretion is 
minimal. Different tracers can be combined with acetate, but most research is performed  
with 11C-Acetate.  
Haseebuddin et al. recently conducted a study in 107 patients with intermediate- or high-risk 
localized primary prostate cancer and negative conventional imaging findings for lymph node 
involvement [41]. They reported a sensitivity and specificity of 68% and 78%, respectively, on a  
per-patient basis using 11C-Acetate in patients with primary disease. Just as 11C-choline it has the 
practical disadvantage that the half-life of 11C is only 20 minutes, requiring an onsite cyclotron. Also a 
shown positive correlation between PSA and 11C-Acetate uptake limits clinical utility [42]. 
2.2.4. 68Ga-Labelled PSMA Ligand 
The latest development in PET imaging is 68Ga-labelled PSMA ligand  
Glu-NH-CO-NH-Lys(Ahx)-HBED-CC. This ligand targets PSMA, which is until now mainly  
a target in scintigraphy.  
Figure 2. 68Ga-PSMA-PET-CT. Patient with prostate cancer (status after brachy-therapy 
and bilateral iliac lymph node dissection, current PSA 21 µg/L). PET images were acquired 
after the administration of 68GA-PSMA-Ligand (60 min thereafter). The figure shows fused 
images (PET-CT): On the coronal view (A) a pathologic isotope uptake in multiple lymph 
nodes in the right para-iliac region and infra-carinal (mediastinum) is clearly visible; the 
corresponding transversal images show the para-iliac (B) and infra-carinal (C) lymph 
nodes with elevated uptake of the tracer. The corresponding transversal native CT images 
present these suspect structures (D,E) as normal sized lymph nodes (marked by  
red arrows). 
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Afshar-Oromich et al. showed promising results in an initial study in 37 patients. They observed 
excellent contrast uptake, also in small lymph nodes (see Figure 2) [43]. In direct comparison to 18F 
labeled Choline, first results suggest that PSMA-targeted imaging performs better in detection of small 
lymph nodes in patients with low PSA values [44]. If these results are reproducible this may have 
significant clinical impact on diagnosing prostatic lymph node metastases. 
2.3. Magnetic Resonance Imaging (MRI)  
MRI is an excellent imaging modality for anatomical information, especially because it provides 
good contrast between different soft tissues. For this paper especially, the functional and molecular 
opportunities of MRI are of interest.  
2.3.1. Diffusion Weighted Imaging (DWI) 
In DWI, molecular diffusion of water molecules is imaged (Brownian motion). The calculated 
apparent diffusion coefficient (ADC) map shows a quantification of the diffusion coefficient. Diffusion 
of benign and metastatic lymph nodes may differ from each other, providing a potential tool for 
differentiation. Few studies have been performed to assess its value for detection of lymph node 
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metastases in prostate cancer. Eiber et al. analyzed lymph nodes of 29 prostate cancer patients with a 
short axis of >6 mm. Ten patients underwent lymphadenectomy with histological correlation of lymph 
nodes. The other 19 were followed up for a mean of 9 months (range 6–12 months). Malignant lymph 
nodes showed restricted diffusion resulting in a lower ADC-value compared to benign lymph nodes. 
Sensitivity and specificity were 86% and 85%, respectively, compared to a size-based analysis at a 
cutoff of 8 mm with sensitivity and specificity of 82% and 54%, respectively [45]. In 2011, this group 
showed similar results for DWI imaging in a smaller group of patients [46]. On the contrary,  
Budiharto et al. reported disappointing results in 2011 in a group of 36 high-risk prostate cancer 
patients with no shown lymph node metastasis on conventional imaging. Minimal axial diameter of 
included lymph nodes was 4 mm. All patients underwent an extended pelvic lymph node dissection. 
Sensitivity for lymph node region-based analysis was only 19% (specificity 98%). In a per-patient 
analysis the sensitivity increased to 43% (specificity 82%) [47]. Similar to Choline PET-CT the 
sensitivity of DWI is especially limited in small lymph nodes. Furthermore, Choline PET-CT seems to 
perform better in terms of specificity.  
2.3.2. Magnetic Resonance Lymphography (MRL) 
In MRL, normal lymph node tissue can be distinguished from metastatic tissue by labeling 
macrophages in normal lymph node tissue using ultra small super paramagnetic iron oxide (USPIO) 
particles. Benign lymph nodes will therefore undergo a change in their magnetic properties. On T2* 
(iron sensitive) images, benign lymph nodes lose their signal in contrast to metastatic lymph nodes 
who have a bright signal (Figure 3). In this way, even small metastases in normal sized lymph nodes 
can be detected [34,48]. Studies, with respectively 80, 50 and 375 patients with primary prostate 
cancer included, have reported a sensitivity and specificity of 88%–92% and 93%–98%, respectively, 
for MRL with ferumoxtran-10 as USPIO agent [48–50]. Triantafyllou et al. [51] recently published a 
study including 75 patients with bladder and/or prostate cancer. In this study only patients with normal 
sized lymph nodes were included and a meticulous histopathological analysis of each lymph node was 
applied. This resulted in a more limited sensitivity and specificity (55%–58% and 83%–85%, 
respectively). The reported inter observer variability was furthermore not negligible, possibly also 
skewing the results [52]. In previous work the same group added a DWI sequence to MRL for faster 
detection of lymph nodes. This significantly shortened study analysis without compromising the study 
results [53]. MRL further improved knowledge about the lymph node pattern of spread.  
Heesakkers et al. showed that in 41% of the patients, histologically confirmed lymph nodes were 
located only outside the area of standard lymph node dissection. In another 41% of patients, 
histologically confirmed metastatic lymph nodes were found both inside and outside this area [6]. 
Meijer et al. showed that 53% of primary prostate cancer patients, with intermediate and high risk with 
non-enlarged lymph nodes, had at least one MRL positive lymph node outside the clinical target 
volume for elective pelvic irradiation as defined by the radiation therapy oncology group [54]. In 
patients with biochemical recurrence, after radical prostatectomy this percentage increased to  
79% [55]. Furthermore, thanks to MRL, the knowledge about the size of lymph node metastasis is 
improved [34,48,51]. Although the results with MRL are promising, USPIO agents, like ferumoxtran-10, 
are currently not available for clinical routine use. 
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Figure 3. MR-lymphography at 3 Tesla using USPIO. Patient with prostate cancer and 
lymphatic metastases. Left image shows the morphological T1 weighted coronal sequence 
with two small lymph nodes near to the left common iliac artery. Right image shows the 
corresponding T2* weighted coronal image 24 h after the intravenous administration of an 
USPIO agent (ferumoxtran-10). The lymph node marked by the green circle shows an 
USPIO uptake and therefore a signal loss in the T2* image suggesting normal lymphatic 
tissue. The lymph node marked by the red circle does not show any USPIO uptake and 
therefore shows a bright signal on the T2* image. This lymph node is highly suspect  
for metastasis. 
 
3. Focal Treatment Options for Lymph Node Metastases 
Improved detection and localization of lymph node metastases opens the door for new  
treatment options.  
There is evidence that patients can benefit from lymph node dissection in a therapeutic  
way [56–59]. Sentinel lymph node imaging and MRL improved our knowledge on where to expect 
metastatic lymph nodes, which can improve the results of a dissection. Limited or isolated lymph node 
metastases detected with molecular and functional imaging techniques may be treated with focal 
therapy. First reports on 11C-choline guided surgery show encouraging results [60,61], as is the case 
for 11C-choline guide robotic image-guided stereotactic radiotherapy [62].  
Also, studies with MRL guided intensity-modulated radiotherapy have shown to be feasible and to 
eliminate metastatic lymph nodes [63,64]. As the results with 68Ga-labelled PSMA ligand PET-CT are 
promising, also in small lymph nodes, 68Ga-labelled PSMA ligand PET-CT guided focal therapy  
is expected. 
4. Conclusions 
Conventional CT and MRI play a limited role in lymph node detection in prostate cancer. Pelvic 
lymph node dissection therefore is a widely used method to evaluate lymph node metastases. This, 
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however, is an invasive technique, which often underestimates the real extent of lymphatic metastases.  
In the last decade, extensive research has been performed in the field of molecular and functional 
imaging trying to solve this problem. The sentinel node imaging increased the knowledge about the 
lymphatic drainage pathway. However, the risk of false negative results using this technique  
is considerable.  
The first generation of radiolabeled antibodies used for lymph node imaging showed limited 
sensitivity and specificity, but the second and third generations of tracers are available now, and the 
preliminary results are promising. 
Choline PET/CT is already an established technique for lymph node imaging in patients with 
prostate cancer, although sensitivity is limited in normal sized lymph nodes. First results on  
11C-choline guided therapy are promising. 
Excellent results have been shown using USPIO enhanced MRL. This technique had been leading 
to further improvement of the knowledge on the pathway of spread and size of metastatic nodes. For 
clinical practice this is a promising technique, as well are the results with MRL guided focal therapy 
promising. Unfortunately, USPIO agents are clinically not available at the moment.  
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